On June 7th, GeLongHui reported that ZheShang Securities pointed out that in 2023, the CSO business income of SH Pharma (601607.SH) is expected to increase by about 50%, and the company will sign a CSO contract with Sanofi with a scale of more than 5 billion yuan in the same year. This contract is one of the largest CSO collaborations in the country in recent years. Based on the incremental release of this contract, it is expected that the company's CSO business will see a significant increase in 2024, and the compliance system and sales capabilities reflected behind the contract with Sanofi may support it in opening up a new window for expanding the CSO business model. The bank believes that SH Pharma's innovative distribution business will continue to grow at a high rate, and considering its strong scarcity, the innovative distribution business is expected to support the company's profitability to stabilize and rebound. Maintained a "shareholding" rating.
研报掘金丨浙商证券：维持上海医药“增持”评级，24年CSO业务或将迎来较大幅度增长
Research reports emerge｜ZheShang Securities recommends Buy Rating for SH Pharma, with 24 years of CSO business likely to see significant growth.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.